Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.560
-0.080 (-4.88%)
At close: Feb 21, 2025, 4:00 PM
1.610
+0.050 (3.21%)
After-hours: Feb 21, 2025, 6:27 PM EST
Outlook Therapeutics Employees
Outlook Therapeutics had 23 employees as of September 30, 2024. The number of employees decreased by 1 or -4.17% compared to the previous year.
Employees
23
Change (1Y)
-1
Growth (1Y)
-4.17%
Revenue / Employee
n/a
Profits / Employee
-$2,035,255
Market Cap
49.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
OTLK News
- 3 days ago - Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 8 days ago - Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewsWire
- 18 days ago - Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 22 days ago - Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug - Benzinga
- 5 weeks ago - Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - GlobeNewsWire